Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Alnylam Pharmaceuticals, indicating a negative outlook on the stock.
• Despite this, the company has received several upgrades, with 24 investment analysts rating it as a Buy, reflecting a consensus rating of "Moderate Buy."
• The stock was down 1.9% on a recent trading day, hitting a price of $450.68, amidst high trading volume.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

ALNY has been the subject of several other reports. Wolfe Research upgraded Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Needham & Company LLC upped their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. HC Wainwright restated a "buy" rating and set a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, September 2nd. Finally, Piper Sandler upped their target price on Alnylam Pharmaceuticals from $304.00 to $449.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Twenty-four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $448.04.

Alnylam Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ:ALNY traded down $8.90 during trading on Wednesday, hitting $450.68. 929,838 shares of the company's stock traded hands, compared to its average volume of 979,788. The company has a 50-day moving average price of $446.70 and a 200-day moving average price of $341.95. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $484.21. The company has a market cap of $59.08 billion, a price-to-earnings ratio of -182.46 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.86. The firm had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business's quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jeffrey V. Poulton sold 3,821 shares of the business's stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares of the company's stock, valued at $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael W. Bonney sold 11,250 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the sale, the director directly owned 16,804 shares in the company, valued at $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after acquiring an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after buying an additional 33,696 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Alnylam Pharmaceuticals by 5.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock worth $946,466,000 after acquiring an additional 185,783 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock worth $779,857,000 after buying an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after purchasing an additional 486,489 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.